Swiss National Bank Cuts Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT)

Swiss National Bank lessened its stake in Corcept Therapeutics Incorporated (NASDAQ:CORTGet Rating) by 13.4% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 224,665 shares of the biotechnology company’s stock after selling 34,700 shares during the period. Swiss National Bank’s holdings in Corcept Therapeutics were worth $5,343,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Maryland State Retirement & Pension System lifted its holdings in shares of Corcept Therapeutics by 0.9% in the 2nd quarter. Maryland State Retirement & Pension System now owns 38,749 shares of the biotechnology company’s stock worth $921,000 after acquiring an additional 360 shares during the last quarter. Trustcore Financial Services LLC lifted its holdings in shares of Corcept Therapeutics by 0.3% in the 1st quarter. Trustcore Financial Services LLC now owns 208,806 shares of the biotechnology company’s stock worth $4,702,000 after acquiring an additional 570 shares during the last quarter. State of Tennessee Treasury Department lifted its holdings in shares of Corcept Therapeutics by 1.0% in the 1st quarter. State of Tennessee Treasury Department now owns 76,933 shares of the biotechnology company’s stock worth $1,732,000 after acquiring an additional 763 shares during the last quarter. Mutual of America Capital Management LLC lifted its holdings in shares of Corcept Therapeutics by 6.0% in the 1st quarter. Mutual of America Capital Management LLC now owns 13,738 shares of the biotechnology company’s stock worth $309,000 after acquiring an additional 783 shares during the last quarter. Finally, Acadian Asset Management LLC lifted its holdings in shares of Corcept Therapeutics by 3.3% in the 1st quarter. Acadian Asset Management LLC now owns 31,845 shares of the biotechnology company’s stock worth $716,000 after acquiring an additional 1,032 shares during the last quarter. Hedge funds and other institutional investors own 78.46% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on CORT shares. Truist Financial lowered shares of Corcept Therapeutics to a “hold” rating in a report on Tuesday, August 9th. HC Wainwright upped their price target on shares of Corcept Therapeutics from $29.00 to $33.00 and gave the company a “buy” rating in a report on Thursday, August 4th. Finally, StockNews.com upgraded shares of Corcept Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Sunday, November 20th. One investment analyst has rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $32.00.

Corcept Therapeutics Stock Down 0.2 %

NASDAQ:CORT opened at $25.99 on Friday. Corcept Therapeutics Incorporated has a 52 week low of $15.82 and a 52 week high of $30.14. The firm has a market capitalization of $2.80 billion, a P/E ratio of 25.99, a P/E/G ratio of 2.52 and a beta of 0.56. The company has a fifty day moving average of $26.64 and a 200 day moving average of $25.24.

Insiders Place Their Bets

In other Corcept Therapeutics news, insider Sean Maduck sold 25,000 shares of the company’s stock in a transaction on Monday, October 3rd. The shares were sold at an average price of $25.64, for a total value of $641,000.00. Following the completion of the transaction, the insider now directly owns 56,462 shares in the company, valued at approximately $1,447,685.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Corcept Therapeutics news, insider Sean Maduck sold 25,000 shares of the company’s stock in a transaction on Monday, October 3rd. The shares were sold at an average price of $25.64, for a total value of $641,000.00. Following the completion of the transaction, the insider now directly owns 56,462 shares in the company, valued at approximately $1,447,685.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Gary Charles Robb sold 4,814 shares of the company’s stock in a transaction on Tuesday, November 22nd. The stock was sold at an average price of $26.03, for a total transaction of $125,308.42. Following the completion of the transaction, the insider now owns 21,329 shares of the company’s stock, valued at $555,193.87. The disclosure for this sale can be found here. In the last ninety days, insiders sold 114,814 shares of company stock worth $2,969,158. 18.60% of the stock is currently owned by corporate insiders.

Corcept Therapeutics Company Profile

(Get Rating)

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery.

Recommended Stories

Want to see what other hedge funds are holding CORT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Corcept Therapeutics Incorporated (NASDAQ:CORTGet Rating).

Institutional Ownership by Quarter for Corcept Therapeutics (NASDAQ:CORT)

Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.